Gene Panel and probe for detecting generic cancer species and application of gene Panel and probe

Abstract

The invention discloses a gene Panel for detecting a generic cancer species, a probe and application of the gene Panel. The gene Panel comprises a tumor pathway related gene, a tumor genetic susceptibility gene, a tumor high-frequency mutant gene, a tumor targeted drug related gene, a tumor driving gene, an immune therapeutic effect related gene, a key DDR pathway related gene and other genes playing an important role in cancer generation and development. The gene Panel can be used for detecting all biomarkers corresponding to solid tumor targeted drugs approved by the State Drug Administration (NMPA) / American Food and Drug Administration (FDA) to appear in the market at a time, so that accurate treatment of tumors is fully guided. Prognosis of a subject can be evaluated, the recurrence risk of the subject is layered, and postoperative adjuvant therapy is guided; besides, hereditary tumor evaluation can be carried out on a subject, family genetic risks are prompted, and early discovery, early diagnosis and early treatment are achieved.

Description

technical field [0001] The invention relates to the technical field of tumor multi-gene detection, in particular to a gene panel, probe and application for detecting pan-cancer species. Background technique [0002] According to statistics from the National Cancer Center, in 2015, the number of new cancer cases in my country was 186.39 / 100,000, and the death rate was 105.84 / 100,000. Clinical studies classify tumors as a genetic disease, which is mainly caused by the activation of proto-oncogenes or the inactivation of inhibitory genes. With the great progress of high-throughput sequencing (NGS) and biotechnology, multiple driver genes related to the occurrence and development of cancer and biomarkers that can be used to guide tumor treatment have been discovered, and a number of driver genes and biomarkers have been developed. In clinical treatment, precise treatment can be carried out based on detected driver gene mutations or biomarkers. So far, the treatment mode of tumo...

AI Technical Summary

Problems solved by technology

Among them, although Sanger sequencing is the gold standard for sequencing, because the sequencing technology can only obtain one sequence in one reaction, the sequencing throughput is low; although the price of a single reaction is low, the cost of obtaining a large number of sequencing is high; the detection sensitivity is low, generally Only mutations with a mutation abundance above 20% can be detected, and some low-frequency mutations may be missed

RT-PCR can only detect known sites and cannot discover unknown sites

IHC is mainly used to detect protein expression, and cannot detect gene point mutations (SNV), small fragment insertion-deletion (Indel), etc. Therefore, the detection of medication that needs to be guided by gene SNV / Indel cannot be achieved by IHC

Although FISH detection is the gold standard for identifying gene fusion (Fusion) and amplification (CNV), it is also not applicable to the detection of SNV / Indel

Images